Marketing approval of mogamulizumab

Figures & data

Figure 1. IgG antibody N-glycosylation

Figure 2. Antibody glycosylation: human, recombinant and glyco-engineered

Table 1. Selected antibody glyco-engineering technologies (biobetter or next-generation mAbs)

Company (country)	Technology	Cell line	Antigen target	Reference
GenmAb (NL)	Galactosylation (CDC)	NS0 (mice)	CD20	^26
Glycode (FR)	GlycodExpress®	Yeast		www.glycode.fr
Glycotope (GE)	Glycoexpress®	Human	EGFR, HER2	^28
Greenovation (GE)	BryoMaster™	Physcomitrella patensi (Moss)		^29
Kyowa Hakko Kirin (JP) Lonza (UK)	POTELLIGENT®	CHO (hamster)	CCR4,CD98, GM2, IL5	^30
BioWa (JP), Lonza (UK)	POTELLIGENT®CHOK1SV	CHO-GS0
CNRS (FR)	Baculovirus expressing GNT-I, GNT-II and β1–4 galactosyltransferase	Baculovirus/ Insect cell		^14
LFB (FR)	EMABling®	YB2/0 (rat)	CD20, Rhesus D	^31
Merck-GlycoFi (US)		Pichia pastoris (yeast)	CD20, HER2	^32
Roche-Glycart (CH)	GlycoMAb®	CHO (hamster)	CD20,EGFR, HER2, HER3	^33
Synthon-Biolex (NL)	LEX System	Lemna minor (aquatic plant)	CD20, HER2	^25
SiaMedExpress (FR)	SiaMedExpress®	CHO (hamster)	Not disclosed
Vivalis (FR)	EB66®	EB66 (duck)	CD20	^23

Scientific term abbreviations: CCR4, C-C chemokine receptor type 4; CD, cluster of differentiation; CHO, Chinese hamster ovary; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; IL, interleukin. Country abbreviations: CH, Switzerland; GE, Germany; FR, France; JP, Japan; NL, The Netherlands; UK, United Kingdom; US, United States.

Table 2. Glyco-engineered antibodies in clinical study

Company	Name (INN or company code)	Target	Format; glyco-engineering technology	Status
Kyowa Hakko Kirin	Mogamulizumab, KW0761, AMG761	CCR4	Humanized IgG1; POTELLIGENT®	Approved in Japan
Kyowa Hakko Kirin/ MedImmune	Benralizumab, KHK4563, MEDI-563	IL5 receptor	Humanized IgG1; POTELLIGENT®	Phase 2
MedImmune / Kyowa Hakko Kirin	MEDI-551	CD19	Humanized IgG1; POTELLIGENT®	Phase 2
Kyowa Hakko Kirin	BIW-8962	GM2 ganglioside	Humanized IgG1/3; POTELLIGENT®	Phase 2
Kyowa Hakko Kirin	KHK2898	CD98	Human; POTELLIGENT®	Phase 1
Kyowa Hakko Kirin	KHK2804, CEP-37250	Tumor glycan	Humanized; POTELLIGENT®	Phase 1
Kyowa Hakko Kirin	KHK2866	HB-EGF	Human; POTELLIGENT®	Phase 1
Genentech/Roche	Obinutuzumab, GA101, RO5072759	CD20	Humanized IgG1; GlycoMab^TM	Phase 3
Genentech/Roche	GA201, RG7160, RO5083945	EGFR	Humanized IgG1; GlycoMab^TM	Phase 2
Genentech/Roche	RG7116, RO5479599	HER3	Humanized; GlycoMab^TM	Phase 1
Glycotope	GT-MAB2.5GEX,	MUC-1	Humanized; GlycoExpress^TM	Phase 1
Glycotope	GT-MAB5.2GEX, CetuGEX	EGFR	Chimeric; GlycoExpress^TM	Phase 1
Glycotope	GT-MAB7.3GEX, TrasGEX	HER2	Human; GlycoExpress^TM	Phase 1
Life Science Pharmaceuticals	Ecromeximab, KW-2871	GD3	Chimeric IgG1; YB2/0 cell line	Phase 2
LFB	Roledumab, LFB-R593	Rhesus D	Human IgG1; YB2/0 cell line	Phase 2
LFB / TG Therapeutics	Ublituximab, LFB-R603, TGTX-1101	CD20	Chimeric IgG1; YB2/0 cell line	Phase 1

Note: Based on data available as of May 15, 2012. Abbreviations: CCR4, C-C chemokine receptor type 4; CD, cluster of differentiation; CHO, Chinese hamster ovary; EGFR, epidermal growth factor receptor; HB-EGF, heparin-binding EGF-like growth factor; HER, human epidermal growth factor receptor; IL, interleukin; MUC, mucin.

Gramer MJ, Eckblad JJ, Donahue R, Brown J, Shultz C, Vickerman K, et al. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 2011; 108:1591 - 602; http://dx.doi.org/10.1002/bit.23075; PMID: 21328321

 PubMed Web of Science ®Google Scholar

Lugovskoy AA, Reichert JM, Beck A. 7th Annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. MAbs 2012; 4:134 - 52; http://dx.doi.org/10.4161/mabs.4.2.19426; PMID: 22453093

 PubMedGoogle Scholar

Decker EL, Reski R. Glycoprotein production in moss bioreactors. Plant Cell Rep 2012; 31:453 - 60; http://dx.doi.org/10.1007/s00299-011-1152-5; PMID: 21960098

 PubMed Web of Science ®Google Scholar

Yamane-Ohnuki N, Satoh M. Production of therapeutic antibodies with controlled fucosylation. MAbs 2009; 1:230 - 6; http://dx.doi.org/10.4161/mabs.1.3.8328; PMID: 20065644

 PubMed Web of Science ®Google Scholar

Cérutti M, Golay J. Lepidopteran cells, an alternative for the production of recombinant antibodies?. MAbs 2012; 4:294 - 309; http://dx.doi.org/10.4161/mabs.19942; PMID: 22531440

 PubMed Web of Science ®Google Scholar

Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2:14 - 9; http://dx.doi.org/10.4161/mabs.2.1.10789; PMID: 20081379

 PubMed Web of Science ®Google Scholar

Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 2011; 3:289 - 98; http://dx.doi.org/10.4161/mabs.3.3.15532; PMID: 21487242

 PubMed Web of Science ®Google Scholar

Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119:5118 - 25; http://dx.doi.org/10.1182/blood-2012-02-408773; PMID: 22438256

 PubMed Web of Science ®Google Scholar

Gasdaska JR, Sherwood S, Regan JT, Dickey LF. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol 2012; 50:134 - 41; http://dx.doi.org/10.1016/j.molimm.2012.01.001; PMID: 22305040

 PubMed Web of Science ®Google Scholar

Olivier S, Jacoby M, Brillon C, Bouletreau S, Mollet T, Nerriere O, et al. EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs 2010; 2:405 - 15; PMID: 20562528

 PubMed Web of Science ®Google Scholar